ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Basic/Clinical Science Session

New Therapeutic Targets in AKI

November 05, 2021 | 10:30 AM - 12:30 PM

Location: Live-Stream, Virtual Only

Session Description

Despite recent advances in our understanding of the complex pathophysiology of AKI, we lack effective therapies to treat AKI. In this context, unbiased approaches to identify "draggable targets," patient-centered strategies, and renal targeting solutions are proposed to develop effective therapeutics. This session discusses advances in mechanisms and potential therapeutics in AKI.

Learning Objective(s)

  • Discuss the role of CDKL5 in renal cell death and kidney dysfunction through suppression of pro-survival transcription factor Sox9 
  • Examine the role of the UDP-glucose/P2Y14 receptor axis as a potential target for the attenuation of ischemic AKI
  • Discuss the importance of PXR/AKR1B7 signaling in protecting against AKI and improving mitochondrial metabolism
  • Explain the role of renal-targeting drug carriers as a potential strategy for improving the therapeutic efficacy in AKI

Learning Pathway(s)

  • Acute Kidney Injury

Moderators

  • Takashi Hato, MD
  • Prabhleen Singh, MD, MPH

Presentations

  • CDKL5-SOX9 Axis Drives Epithelial Cell Death in AKI
    10:30 AM - 11:00 AM
    Navjot Singh P. Pabla, PhD
  • Proinflammatory P2Y14 Receptor Signaling in Ischemic AKI
    11:00 AM - 11:30 AM
    Sylvie Breton, MS, PhD
  • Non-Coding RNAs as Potential Therapeutic Targets in AKI
    11:30 AM - 12:00 PM
    Johan M. Lorenzen, MD, PhD
  • Activation of Th17 Cells in Kidney Injury
    12:00 PM - 12:30 PM
    David P. Basile, PhD